VivoSeq
Oncology

Anal Cancer

1

Pipeline Programs↗

4

Active Trials↗

3

Companies Involved↗

Anal Cancer is an early-stage landscape with 1 program across 3 companies. The most active players are Roche, Incyte, Boehringer Ingelheim.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

80/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 2Incyte logo

Incyte

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Retifanlimab

Incyte

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

2programs
Small molecule150%
Monoclonal antibody150%

Modality classified for 100% of 2 pipeline programs.

Analysis

Trial Status

10

clinical trials

Completed4 · 40%
Recruiting3 · 30%
Withdrawn1 · 10%
Unknown status1 · 10%
Active, not recruiting1 · 10%

Clinical Trials

Trial Activity

10 trials

Adaptive Radiation in Anal Cancer
Recruiting·—·N/A·NCT05838391·20 enrolled
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT04929028·40 enrolled
ctHPVDNA Adapted ChemoRadiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer (CHART-AC)
Recruiting·—·Phase 2·NCT07425054·33 enrolled
SAVE THE BOTTOMS!!!: ASSESSING THE GAY MALE EXPERIENCE WITH ANAL CANCER PREVENTION STRATEGIES
Active, not recruiting·UUniversity of Minnesota·N/A·NCT05628194·92 enrolled
Vectibix for the Treatment of Anal Cancer
Completed·GGrupo Espanol Multidisciplinario del Cancer Digestivo·Phase 2·NCT01285778·58 enrolled
Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer
Completed·AAIDS Malignancy Consortium·Phase 2·NCT00324415·45 enrolled
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
Completed·AAIDS Malignancy Consortium·Phase 3·NCT02135419·4,446 enrolled
SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia
Completed·National Cancer Institute (NCI)·Phase 1/2·NCT00052897·18 enrolled
A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer
Withdrawn·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2·NCT04499352
International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel
Unknown status·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT02051868·80 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)